|
Aug 5
|
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 5
|
ImmunityBio: Q2 Earnings Snapshot
|
|
Aug 5
|
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
|
|
Aug 1
|
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations
|
|
Jul 31
|
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
|
|
Jul 25
|
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
|
|
Jul 25
|
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
|
|
Jul 23
|
ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency
|
|
Jul 11
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 24
|
ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA
|
|
May 27
|
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
|
|
Apr 9
|
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple
|
|
Apr 8
|
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
|
|
Mar 7
|
Top Growth Companies With Insider Stakes For March 2025
|
|
Mar 5
|
US High Growth Tech Stocks to Watch in March 2025
|
|
Feb 13
|
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
|
|
Dec 30
|
High Growth Tech Stocks to Watch in December 2024
|
|
Jul 31
|
Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop
|
|
Jun 20
|
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
|
|
May 17
|
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
|